Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
812 Reprograming of tumor-associated myeloid cells by TLR9-targeted STAT3 antisense oligonucleotides sensitizes malignant glioma to PD1-specific immunotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.
